Press Release
Angel Pharmaceuticals Appoints Dr. Erik J. Verner, Ph.D., as Senior Vice President
Jiaxing, China and Burlingame, California., March 17，2022 – Angel Pharmaceuticals Co., Ltd. (“Angel Pharma”) is pleased to announce the appointment of Erik J. Verner as Senior Vice President of Research, who will base in Burlingame, California. Dr. Verner will lead Angel Pharma’s global discovery team.
Dr. Verner joins Angel Pharma with decades of extensive experience in medicinal chemistry, with a proven track record in small-molecule drug discovery research exemplified by two drugs approved. Dr. Verner is one of the three inventors of the core patent of the first FDA approved BTK inhibitor Ibrutinib (IMBRUVICA®). Before joining Angel Pharma, Dr. Verner served as VP of Chemistry at Pardes Biosciences. Prior to that, he served as VP of Medicinal Chemistry at Corvus Pharmaceuticals as well as other leading biotech companies including Pharmacyclics and Principia BioPharma.
Angel Pharma is developing the first-and-only ITK inhibitor in clinical development and the new generation of BTK inhibitors. Dr. Verner's joining will greatly accelerate the development process.
Dr. Verner holds a Ph.D. in chemistry from the University of Pittsburgh and a B.S. in chemistry from the University of Idaho.
About Angel Pharmaceuticals
Angel Pharmaceuticals is a privately held biopharmaceutical company developing a pipeline of precisely targeted investigational medicines for cancer, autoimmune, infectious and other serious diseases. Angel Pharmaceuticals was launched with strategic collaboration with U.S. biopharmaceutical company Corvus Pharmaceuticals, Inc., with investments from Zhejiang Puissance Capital, Hisun Pharmaceuticals, Tigermed and fund associated with Betta Pharmaceuticals. Angel Pharmaceuticals has been developing a diversified pipeline portfolio, its initial pipeline includes licensed rights to develop and commercialize three clinical-stage candidates, mupadolimab, CPI-818 and ciforadenant, in greater China, and global commercial and intellectual property rights for a pre-clinical stage new generation of BTK inhibitors. For more information, visit www.angelpharma.com
